IPO (completed 2019)

Ascelia Pharma completed an Offering and listing Nasdaq Stockholm in March 2019

  • The Offering was made to the general public in Sweden and Denmark and to institutional investors in Sweden and abroad.
  • The Offering comprised a maximum of 8,000,000 shares corresponding to SEK 200 million
  • The subscription price was SEK 25 per share
  • Subscription period: 21 February 2019 to 5 March 2019
  • First day of trading was 13 March 2019
  • The shares are listed on Nasdaq Stockholm (small cap) under the ticker “ACE”


Subscription undertakings:

Alto Investment, Handelsbanken Fonder and the Fourth Swedish National Pension Fund (AP4) and a number of existing shareholders, including Sunstone Capital and Øresund-Healthcare Capital as well as board members and senior executives, and other external investors, undertook to subscribe for shares in the Offering for a total of SEK 150 million


Press releases

190412 – Exercise of over-allotment option (ENG)

190411 – Stabilisation notice (ENG)

190401 – Stabilisation notice (ENG)

190321 – Stabilisation notice (ENG)

190312 – IPO first day of trading announcement (ENG)

190306 – Result of the IPO (ENG)

190220 – Press Release IPO (ENG)

Download Prospectus

Prospectus 20 Feb 2019

Danish summary of Prospectus 20 Feb 2019